<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25207" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mixed Connective Tissue Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sapkota</surname>
            <given-names>Binita</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Khalili</surname>
            <given-names>Yasir</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Binita Sapkota declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasir Al Khalili declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25207.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Mixed connective tissue disease is a rare autoimmune disease characterized by the presence of the anti-U1-ribonucleoprotein, Raynaud phenomenon, and features of at least&#x000a0;2 connective tissue diseases, including systemic lupus erythematosus, systemic sclerosis, inflammatory myositis, and rheumatoid arthritis. Diagnosis can be challenging due to variable and diverse presenting symptoms and changes in symptoms over time. Nonsteroidal anti-inflammatory drugs, steroids, and immunosuppressive agents are the mainstays of treatment.</p>
        <p>This activity reviews the latest knowledge and clinical skills necessary to accurately diagnose and effectively manage patients with mixed connective tissue disease.&#x000a0;Participants gain an in-depth&#x000a0;understanding of the pathophysiology, clinical manifestations, diagnostic criteria, and emerging treatment options for this complex autoimmune condition. This activity also highlights the role of an interprofessional healthcare team in&#x000a0;successfully collaborating to&#x000a0;provide comprehensive care for patients with mixed connective tissue disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients presenting with symptoms and signs of mixed connective tissue disease.</p></list-item><list-item><p>Differentiate mixed connective tissue disease from other autoimmune rheumatologic conditions based on clinical features and laboratory findings.</p></list-item><list-item><p>Assess&#x000a0;evidence-based treatment options for patients affected by mixed connective tissue disease.</p></list-item><list-item><p>Collaborate with an&#x000a0;interprofessional healthcare team to provide comprehensive care and optimal outcomes for patients with&#x000a0;mixed connective tissue disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25207&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25207">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25207.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Mixed connective tissue disease (MCTD) is a rare systemic autoimmune disease with the main features of at least&#x000a0;2 overlapping connective tissue diseases, including systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, and rheumatoid arthritis.&#x000a0;The disease is also defined by the presence of anti-U1-ribonucleoprotein (RNP) antibodies and Raynaud phenomenon.<xref ref-type="bibr" rid="article-25207.r1">[1]</xref><xref ref-type="bibr" rid="article-25207.r2">[2]</xref>&#x000a0;The condition was initially described by Sharp in 1972 through a case series of 25 patients with features of systemic lupus erythematosus, systemic sclerosis, and inflammatory muscle disease associated with anti-U1-RNP antibodies. However, at that time, MCTD was not described as a separate entity from undifferentiated connective tissue disease, and its characteristics have evolved since then. Although most authors describe MCTD as an independent entity, some believe it may represent an early stage of a definite connective tissue disease,&#x000a0;such as systemic lupus erythematosus, systemic sclerosis, or overlap syndrome. MCTD has no unique clinical features, and considerable interindividual variation in clinical manifestations exists.</p>
        <p>Multiple attempts have been made to develop classification criteria, but there are currently no internationally agreed-upon diagnostic criteria.&#x000a0;Most clinicians agree on a diagnosis if the following criteria are met:<xref ref-type="bibr" rid="article-25207.r3">[3]</xref><xref ref-type="bibr" rid="article-25207.r4">[4]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The presence of&#x000a0;a high titer of positive anti-U1-RNP, and</p>
          </list-item>
          <list-item>
            <p>Raynaud phenomenon, puffy digits, or hand edema</p>
          </list-item>
        </list>
        <p>And&#x000a0;at least&#x000a0;2 of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Synovitis</p>
          </list-item>
          <list-item>
            <p>Myositis</p>
          </list-item>
          <list-item>
            <p>Leukopenia</p>
          </list-item>
          <list-item>
            <p>Esophageal dysmotility</p>
          </list-item>
          <list-item>
            <p>Pleuritis</p>
          </list-item>
          <list-item>
            <p>Pericarditis</p>
          </list-item>
          <list-item>
            <p>Interstitial lung disease</p>
          </list-item>
        </list>
        <p>In 2019, a&#x000a0;consensus panel in Japan proposed another&#x000a0;revised set of diagnostic criteria for MCTD, which divides the disease features into&#x000a0;4 categories.<xref ref-type="bibr" rid="article-25207.r5">[5]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The presence of&#x000a0;a high titer of positive anti-U1-RNP, and</p>
          </list-item>
          <list-item>
            <p>Raynaud phenomenon, puffy digits, or hand edema</p>
          </list-item>
        </list>
        <p>And either&#x000a0;1 of the following organ involvements or at least&#x000a0;2 overlapping manifestations:</p>
        <p>Organ involvement includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary arterial hypertension</p>
          </list-item>
          <list-item>
            <p>Aseptic meningitis</p>
          </list-item>
          <list-item>
            <p>Trigeminal neuropathy</p>
          </list-item>
        </list>
        <p>Overlapping manifestations include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic lupus erythematosus: polyarthritis, lymphadenopathy, malar rash, pericarditis or pleuritis, leukopenia or thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Systemic sclerosis: sclerodactyly, interstitial lung disease, esophageal dysmotility or dilatation</p>
          </list-item>
          <list-item>
            <p>Inflammatory myositis: muscle weakness, elevated levels of myogenic enzymes, myogenic abnormalities on electromyogram</p>
          </list-item>
        </list>
        <p>Diagnosis is based on at least&#x000a0;1 common manifestation, immunological manifestation, and either&#x000a0;1 characteristic organ involvement or at least&#x000a0;1 feature in&#x000a0;2 or more overlapping manifestations. These criteria have a sensitivity of 90.6% and a specificity of 98.4%, although they have not been formally adopted by the international community.<xref ref-type="bibr" rid="article-25207.r6">[6]</xref></p>
      </sec>
      <sec id="article-25207.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of&#x000a0;MCTD is unclear but is believed to involve the interaction of genetic predisposition with the environment.&#x000a0;Sequence-based typing of HLA-B* and DRB1* showed that risk alleles for MCTD are HLA-B*08 and DRB1*04:01, whereas protective alleles are DRB1*04:04,&#x000a0;DRB1*13:01, and&#x000a0;DRB1*13:02.<xref ref-type="bibr" rid="article-25207.r7">[7]</xref></p>
        <p>No clear environmental risk factor has been identified thus far. However, immune activation due to environmental factors in people with genetic predisposition is believed to play a role. Some environmental factors, such as infections, drugs, toxins, ultraviolet radiation, and chemicals, including vinyl chloride and silica, have some correlation with the development of MCTD.<xref ref-type="bibr" rid="article-25207.r8">[8]</xref></p>
        <p>Molecular mimicry is the leading theory triggering the onset of disease. Amino acid sequences from non-self proteins in the environment may mimic host epitopes and induce autoantibody responses. For example, almost 91% of DNA from the serum of patients with MCTD had an HIV type-1 conserved Pol sequence.<xref ref-type="bibr" rid="article-25207.r9">[9]</xref>&#x000a0;Seventy-five percent of patients with MCTD patients had antibodies to HIV GAG proteins p35 and p24.<xref ref-type="bibr" rid="article-25207.r10">[10]</xref></p>
      </sec>
      <sec id="article-25207.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>MCTD&#x000a0;is a rare disease, and its exact incidence is unknown. In a population-based study from Olmsted County, Minnesota, the incidence of MCTD was 1.9 per 100,000 adults per year. The mean age of diagnosis was 48 years, and 84% of those affected were female.<xref ref-type="bibr" rid="article-25207.r11">[11]</xref></p>
        <p>In a study of the Norwegian population, the incidence of MCTD was 2.1 per million per year, the female-to-male ratio was 3.3 to 1, and the mean age at diagnosis was 37.9 years.<xref ref-type="bibr" rid="article-25207.r12">[12]</xref>&#x000a0;</p>
        <p>In a French cohort study involving 330 patients over a median time of 8 years, 88% were female, with a median age of 35.<xref ref-type="bibr" rid="article-25207.r13">[13]</xref>&#x000a0;This disease affects all races, and its clinical manifestations seem to be similar in all racial/ethnic groups, although some differences are emerging in population-based reports.&#x000a0;</p>
      </sec>
      <sec id="article-25207.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Raynaud phenomenon and pulmonary hypertension are typical clinical manifestations supporting abnormal micro- and macrovascular circulation. Nail-fold capillary abnormalities are demonstrated by nail-fold capillaroscopy in up to 41.3% of patients with MCTD.<xref ref-type="bibr" rid="article-25207.r14">[14]</xref><xref ref-type="bibr" rid="article-25207.r15">[15]</xref>&#x000a0;Unlike systemic sclerosis, nail-fold&#x000a0;capillary abnormalities can improve with immunosuppressive therapy.</p>
        <p>Given&#x000a0;the anti-U1-RNP antibody is the hallmark of MCTD, it is believed that the anti-U1-RNP antibody&#x000a0;and its antigen play a role in the pathogenesis of MCTD.<xref ref-type="bibr" rid="article-25207.r16">[16]</xref>&#x000a0;The U1-RNP complex is an intranuclear protein that converts pre-messanger RNA to mature RNA.&#x000a0;This complex comprises 3 specific proteins&#x02014;A, C, and 70 kDa&#x02014;to which anti-U1 RNP antibodies bind. The 70 kDa antigen is the main target of the anti-RNP antibody in MCTD.<xref ref-type="bibr" rid="article-25207.r14">[14]</xref>&#x000a0;The genetic association of MCTD with HLA-DR4 and DR2 phenotypes indicates the involvement of T-cell receptors and HLA molecules in the generation of anti-U1-RNP.<xref ref-type="bibr" rid="article-25207.r17">[17]</xref>&#x000a0;</p>
        <p>Two main mechanisms have been proposed for the pathogenic role of anti-U1-RNP antibodies. The first mechanism involves direct binding to endothelial cells through U1-RNP peptides or recognition of nucleosome RNP fragments in endothelial cell apoptotic blebs.<xref ref-type="bibr" rid="article-25207.r18">[18]</xref><xref ref-type="bibr" rid="article-25207.r19">[19]</xref>&#x000a0;This mechanism may lead to the phenotype involving vascular diseases such as Raynaud phenomenon, skin sclerosis, and pulmonary hypertension. The second possible pathogenic mechanism is through immune complex formation, which can activate the complement cascade and lead to tissue inflammation and damage, such as myositis, arthritis, and interstitial lung disease.</p>
      </sec>
      <sec id="article-25207.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Initial symptoms of&#x000a0;MCTD are typically nonspecific and include arthralgia, malaise, myalgia, and low-grade fever. MCTD can affect nearly any organ system, and symptoms reflect the overlapping nature of this condition with other rheumatological diseases, as there are no unique, singular clinical manifestations of MCTD.</p>
        <p>
<bold>Common Manifestations</bold>
</p>
        <p><bold>Skin: </bold>The most common skin change is Raynaud phenomenon, which is also the most common presenting feature of MCTD, occurring between 50.3% and 93.2% at presentation and 57.5% to 99% after follow-up.<xref ref-type="bibr" rid="article-25207.r20">[20]</xref> Puffy digits, characterized by diffuse soft tissue swelling of the fingers, are also characteristic, although not always present, affecting 53% to 72% of patients at presentation and 46% to 92% after follow-up.<xref ref-type="bibr" rid="article-25207.r20">[20]</xref> Nailfold capillary abnormalities may be present on nailfold capillaroscopy. A scleroderma-like pattern to nailfold capillary abnormalities is the most commonly observed, with early-type lesions being predominant.<xref ref-type="bibr" rid="article-25207.r21">[21]</xref>&#x000a0;Other possible manifestations include hand edema, acrosclerosis, calcinosis cutis, telangiectasia, erythema nodosum, hair loss, and vasculitis of digits. Discoid plaques and a malar rash similar to systemic lupus erythematosus can also occur. Case reports describe panniculitis involving the abdomen, legs,&#x000a0;and breasts.<xref ref-type="bibr" rid="article-25207.r22">[22]</xref><xref ref-type="bibr" rid="article-25207.r23">[23]</xref></p>
        <p><bold>Musculoskeletal:</bold> Patients may develop inflammatory arthritis similar to systemic lupus erythematosus or rheumatoid arthritis, and this type of arthritis is reported&#x000a0;in 65.3% to 86% of patients at the time of presentation and in 49.7% to 89.6% after follow-up.<xref ref-type="bibr" rid="article-25207.r20">[20]</xref>&#x000a0;&#x000a0;</p>
        <p><bold>Muscle: </bold>Inflammatory myopathy, clinically and histologically similar to polymyositis, often manifests as painless proximal muscle weakness with elevated levels of creatinine kinase and aldolase in the serum. This condition is reported in 13.5%&#x000a0;to&#x000a0;27.9% of patients at the time of presentation and in 19%&#x000a0;to 32.5% at follow-up.<xref ref-type="bibr" rid="article-25207.r20">[20]</xref> Rarely, myositis can also be the initial presentation.<xref ref-type="bibr" rid="article-25207.r15">[15]</xref></p>
        <p><bold>Cardiopulmonary:</bold> Pulmonary involvement occurs in almost 73% of patients, with dyspnea being the most common symptom.<xref ref-type="bibr" rid="article-25207.r24">[24]</xref> Other symptoms include dry cough,&#x000a0;pleuritic chest pain, wheezing, and hemoptysis. Interstitial lung disease can occur in 27.8%&#x000a0;to 47% of patients,&#x000a0;with a nonspecific interstitial pneumonitis pattern being the most common.<xref ref-type="bibr" rid="article-25207.r20">[20]</xref>&#x000a0;Pulmonary hypertension can occur in 6.9%&#x000a0;to 17.8% of patients.<xref ref-type="bibr" rid="article-25207.r20">[20]</xref> Other pulmonary manifestations may include&#x000a0;pleural effusion, pulmonary vasculitis, thromboembolic disease, alveolar hemorrhage, infections, and obstructive airway disease.<xref ref-type="bibr" rid="article-25207.r25">[25]</xref>&#x000a0;Pericarditis is the most common variant of cardiac disease involving up to 40% of patients.<xref ref-type="bibr" rid="article-25207.r26">[26]</xref>&#x000a0;Pericardial effusion, mitral valve prolapse, myocarditis, accelerated atherosclerosis, and conduction abnormalities can also occur. Patients with MCTD are also at risk for accelerated atherosclerotic disease.&#x000a0;</p>
        <p><bold>Gastrointestinal:</bold> Esophageal dysmotility leading to dysphagia, odynophagia, gastrointestinal reflux, and regurgitation are all common features, occurring in 34.8% to 38.9% of patients at presentation and in 45.3% to 49.6% during follow-up.<xref ref-type="bibr" rid="article-25207.r20">[20]</xref> Less common manifestations are pancreatitis, megacolon, duodenal bleeding, portal hypertension, and autoimmune hepatitis. Rarely, patients can present with protein-losing enteropathy.<xref ref-type="bibr" rid="article-25207.r27">[27]</xref></p>
        <p>
<bold>Less Common Manifestations</bold>
</p>
        <p><bold>Renal:</bold> Renal involvement is less common and may occur in 15% to 25% of MCTD patients. Most patients are typically asymptomatic.<xref ref-type="bibr" rid="article-25207.r28">[28]</xref> Membranous nephropathy is the most common finding. Nephropathy can sometimes be&#x000a0;associated with significant morbidity, risk of hypertension, and&#x000a0;progressive kidney disease.<xref ref-type="bibr" rid="article-25207.r29">[29]</xref></p>
        <p><bold>Central nervous system:</bold>&#x000a0;The involvement of the central nervous system is increasingly recognized as a manifestation of disease. Nervous system involvement&#x000a0;has been described in&#x000a0;up to 25% of patients.<xref ref-type="bibr" rid="article-25207.r30">[30]</xref> Trigeminal neuralgia is the most common central nervous system manifestation. Other possible symptoms include headaches, peripheral neuropathy, aseptic meningitis, cerebral venous sinus thrombosis, and sensorineural hearing loss.<xref ref-type="bibr" rid="article-25207.r31">[31]</xref></p>
        <p><bold>Hematological involvement:</bold> Anemia, leukopenia, and thrombocytopenia may occur. Idiopathic immune&#x02013;mediated thrombocytopenia and hemolytic anemia are not common manifestations and should prompt further evaluation for systemic lupus erythematosus and other causes.&#x000a0;</p>
      </sec>
      <sec id="article-25207.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluating MCTD requires a comprehensive understanding of its diverse clinical manifestations and overlapping features with other connective tissue diseases. Clinicians must utilize a combination of detailed patient history, physical examination, and targeted diagnostic tests to diagnose and assess MCTD accurately.&#x000a0;</p>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>Laboratory studies are useful for evaluating the presence of the U1-RNP antibody, which is helpful for diagnosis. They are also valuable for characterizing the severity of potential organ involvement and assessing the presence of other features of overlapping autoimmune rheumatologic disease.</p>
        <p>Immunological markers include high titer speckled pattern anti-nuclear antibody (typically &#x0003e;1280) and high titer anti-U1-RNP.&#x000a0;The sensitivity of the U1-RNP antibody is 100%, but its specificity is lower. Another potential marker for MCTD is the presence of survival of motor neuron (SMN) antibody&#x000a0;directed to SMN and its complex. In a study comparing the prevalence of anti-SMN complex antibodies between patients with systemic lupus erythematosus and MCTD, the antibodies were present in 40% of MCTD patients, whereas only 10% of patients with systemic lupus erythematosus had the antibody. In this study, the estimated specificity of the anti-SMN antibody was 91.2% for MCTD.<xref ref-type="bibr" rid="article-25207.r32">[32]</xref></p>
        <p>Patients may have other lab and immunological abnormalities depending on the presence of features of systemic lupus erythematosus, systemic sclerosis, or dermatomyositis. Up to 65% of patients with MCTD may have a positive rheumatoid factor, and 50% of patients can have a positive anti-cyclic citrullinated peptide.<xref ref-type="bibr" rid="article-25207.r33">[33]</xref><xref ref-type="bibr" rid="article-25207.r34">[34]</xref> Muscle enzymes may be elevated. Falsely positive VDRL and reduced complement levels are a feature in some patients. Anti-double-stranded DNA, anticentromere, anti-Scl-70, and anti-PM-1 antibodies are typically absent.</p>
        <p>A complete blood count may demonstrate anemia and leukopenia in almost 75% of patients. Hypergammaglobulinemia is also present in 75% of patients with MCTD. The erythrocyte sedimentation rate is elevated in nearly all patients.<xref ref-type="bibr" rid="article-25207.r2">[2]</xref>&#x000a0;Urinalysis can show proteinuria and hematuria if renal disease is present.</p>
        <p>
<bold>Imaging and Other Diagnostic Studies</bold>
</p>
        <p>Imaging and other diagnostic studies are not necessarily indicated unless there is a suspicion of focal organ involvement. The following diagnostic modalities are not meant to be exhaustive but suggest how certain tests may be used&#x000a0;to diagnose&#x000a0;patients with MCTD and concerns for a focal organ or system problem.</p>
        <p><bold>Cardiopulmonary testing: </bold>The diagnostic procedures used to evaluate the cardiopulmonary&#x000a0;system include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chest x-ray: This technique&#x000a0;may serve as a screening test for lung disease, including pulmonary infiltrates, interstitial lung disease, pleural effusions, and cardiomegaly.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Computed tomography: High-resolution&#x000a0;computed tomography is very sensitive in diagnosing interstitial lung disease. Common findings include ground-glass opacities, linear opacities, subpleural micronodules, septal thickening, and traction bronchiectasis, typically with peripheral and lower lobe predominance. Honeycombing, airspace consolidation, emphysema, and centrilobular nodules are less common findings.<xref ref-type="bibr" rid="article-25207.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Echocardiogram: An echocardiogram is a useful tool for screening for right heart disease and pulmonary hypertension and assessing the pericardium for the presence of effusion or thickening, valvular abnormalities, and overall cardiac function.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary function testing: Patients with interstitial lung disease may show reductions in the diffusion capacity for carbon monoxide, forced vital capacity, and forced expiratory volume.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Right heart catheterization: Definitive diagnosis of pulmonary hypertension in MCTD requires right heart catheterization demonstrating mean pulmonary arterial pressure at rest &#x0003e;20 mmHg.</p>
          </list-item>
        </list>
        <p><bold>Musculoskeletal imaging: </bold>The diagnostic techniques used to visualize and assess the bones, joints, muscles, and soft tissues of the musculoskeletal system are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>X-ray of joints: X-rays of affected joints might reveal&#x000a0;evidence of inflammatory arthritis with erosions, joint space narrowing, and periarticular osteopenia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Musculoskeletal ultrasound:&#x000a0;This imaging modality utilizes ultrasonic sound waves to assess soft tissues, cartilage, bone surfaces, and fluid-containing structures for the presence of abnormalities responsible for joint pain and swelling.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Magnetic resonance imaging of a limb: This technique is another sensitive tool to evaluate for the presence of subclinical or clinically evident inflammatory muscle disease or inflammatory&#x000a0;arthritis.&#x000a0;</p>
          </list-item>
        </list>
        <p>Other tests for evaluating gastrointestinal tract symptoms may include an esophagram, upper endoscopy, or colonoscopy. For assessing potential inflammatory muscle or peripheral nerve disease, an electromyogram and nerve conduction study may be used.</p>
      </sec>
      <sec id="article-25207.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Due to the rarity of the condition, there are no randomized controlled trials to guide the treatment of patients with MCTD. Therapy's general goals are to control symptoms and are directed by clinical manifestations and organ involvement.</p>
        <p>The most significant organ manifestations involve the heart and lungs, with pulmonary hypertension and interstitial lung disease in a nonspecific interstitial pneumonitis pattern being the primary causes of morbidity and mortality.<xref ref-type="bibr" rid="article-25207.r13">[13]</xref>&#x000a0;Therapeutic trials for patients with interstitial lung disease tend to combine patients with MCTD, scleroderma, and other connective tissue diseases, and the management recommendations are extrapolated to MCTD. The main medications used to treat interstitial lung disease are mycophenolate mofetil, cyclophosphamide, and rituximab, with mycophenolate mofetil being the preferred initial therapy due to its comparable efficacy and fewer&#x000a0;adverse effects&#x000a0;compared to cyclophosphamide.<xref ref-type="bibr" rid="article-25207.r36">[36]</xref>&#x000a0;More recently, the RECITAL study of connective tissue disease-interstitial lung disease has shown that rituximab and cyclophosphamide are fairly equivalent in pulmonary outcomes with fewer overall&#x000a0;adverse effects for rituximab.<xref ref-type="bibr" rid="article-25207.r37">[37]</xref></p>
        <p>Pulmonary hypertension is typically less responsive to steroids, and the guidance of an expert in pulmonary hypertension should direct advanced management. Vasodilators such as prostaglandins,&#x000a0;including epoprostenol; endothelin receptor antagonists,&#x000a0;including ambrisentan; phosphodiesterase 5 inhibitors, including sildenafil; and immunosuppression with corticosteroids and cyclophosphamide&#x000a0;may be appropriate therapeutic considerations.</p>
        <p>The management of Raynaud phenomenon includes symptomatic strategies such as avoiding caffeine, smoking, cold temperatures, and injury to the digits. Oral calcium channel blockers, such as nifedipine, which decreases peripheral resistance, are an option. Prostaglandins, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and topical nitroglycerins are also effective.&#x000a0;&#x000a0;</p>
        <p>Arthritis and arthralgia&#x000a0;typically respond to nonsteroidal anti-inflammatory drugs and hydroxychloroquine. For refractory synovitis, corticosteroids, methotrexate, and other disease-modifying anti-rheumatic drugs can be used.</p>
        <p>Pleuritis, pericarditis, myositis, and aseptic meningitis typically respond to steroids. Steroid-sparing agents, such as methotrexate, cyclosporine, azathioprine, and mycophenolate mofetil, are commonly used as second-line agents. Steroid-resistant myositis may respond to intravenous immunoglobulin.</p>
        <p>gastrointestinal reflux treatment involves proton pump inhibitors (PPI) or histamine blockers, lifestyle changes, and dietary modifications, such as elevating the head of the bed and avoiding dietary triggers. Prokinetics and gastric fundoplication are possible options for those who fail twice-daily&#x000a0;PPI therapy. Individuals with esophageal motility disorder may require prokinetics. Patients with malabsorption should be on a lactose-free diet, and medium-chain triglycerides should substitute for long-chain fatty acids.</p>
        <p>Patients with autoimmune hemolytic anemia and thrombocytopenia are initially treated with steroids. Clinicians can consider rituximab in resistant cases.</p>
      </sec>
      <sec id="article-25207.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Due to nonspecific symptoms and different organ involvement, MCTD mimics several other conditions, especially other connective tissue diseases. Differential diagnoses are&#x000a0;as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic lupus erythematosus is an autoimmune disease characterized by the presence of an anti-nuclear antibody and varied manifestations, which may include inflammatory arthritis, mucocutaneous disease, serositis, pleuritis, pericarditis, renal disease, fevers, neuropsychiatric symptoms, leukopenia, autoimmune hemolysis, thrombocytopenia, antiphospholipid antibodies, low complements, and the presence of an anti-double stranded DNA antibody or anti-Smith antibody.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatoid arthritis is typically symmetric polyarthritis, predominantly affecting the small joints of the hands, wrists, ankles, and feet. Up to 70% of patients have an abnormal rheumatoid factor and anti-cyclic citrullinated peptide antibody.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Polymyositis is an idiopathic inflammatory myositis that causes proximal over distal muscle weakness.&#x000a0;This condition&#x000a0;is associated with abnormal muscle biochemistries, signs of muscle edema or inflammation on magnetic resonance imaging, and the absence of autoantibodies.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dermatomyositis is an idiopathic inflammatory myositis similar to polymyositis but includes varying presentations involving the skin, lungs, gastrointestinal tract, and joints. This condition is typically associated with either myositis-specific antibodies or myositis-associated antibodies.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Scleroderma is a chronic multisystem disease characterized by widespread vascular dysfunction and progressive fibrosis of the skin and internal organs, which is associated with autoimmunity.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25207.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>MCTD generally has a good prognosis, although&#x000a0;it depends on which organ is affected, the degree of inflammation, and the rate of disease progression.<xref ref-type="bibr" rid="article-25207.r1">[1]</xref><xref ref-type="bibr" rid="article-25207.r20">[20]</xref>&#x000a0;The mortality rate varies between 3.1% and 10% in the literature.<xref ref-type="bibr" rid="article-25207.r13">[13]</xref><xref ref-type="bibr" rid="article-25207.r3">[3]</xref></p>
        <p>In a study involving the Hungarian population, the survival rate for 5 and 10 years after diagnosis was 98% and 96%, respectively. In a French cohort study involving 330 patients with MCTD followed up on average for 8 years, 45.2% of patients achieved remission, 7.6% developed pulmonary hypertension, and 27.9% developed interstitial lung disease.<xref ref-type="bibr" rid="article-25207.r13">[13]</xref></p>
        <p>Pulmonary hypertension is the most common cause of death. Interstitial lung disease, infections, cardiovascular complications, and malignancies are other causes.<xref ref-type="bibr" rid="article-25207.r38">[38]</xref>&#x000a0;The presence of immunoglobulin G anticardiolipin antibodies may&#x000a0;be associated with more severe disease.&#x000a0;</p>
        <p>The identification of the anti-SMN complex antibodies also has prognostic significance. MCTD patients with this autoantibody had poorer disease-related outcomes compared to patients who did not have this autoantibody, and complications were mainly related to pulmonary hypertension and interstitial lung disease.<xref ref-type="bibr" rid="article-25207.r6">[6]</xref>&#x000a0;The anti-Ro52 autoantibody also portends a worse prognosis in those with MCTD, specifically related to the severity of interstitial lung disease.<xref ref-type="bibr" rid="article-25207.r39">[39]</xref>&#x000a0;</p>
        <p>Epitope spreading, or the development of new autoantibodies during the disease course, can lead to changes in clinical features. For example, a lower rate of skin sclerosis and a higher percentage of interstitial lung disease appeared in patients with epitope spreading compared to those who did not during a follow-up of patients with MCTD.<xref ref-type="bibr" rid="article-25207.r40">[40]</xref>&#x000a0;In addition, patients with MCTD can clinically progress to other CTDs, such as systemic sclerosis, rheumatoid arthritis, Sjogren syndrome, and systemic lupus erythematosus. In a retrospective review&#x000a0;involving patients with MCTD followed over a median time of 8 years from diagnosis, approximately 25.6% evolved to a definite connective tissue disease.<xref ref-type="bibr" rid="article-25207.r13">[13]</xref>&#x000a0;On the other hand, patients with other connective tissue diseases or undifferentiated connective tissue diseases can eventually develop MCTD.&#x000a0;</p>
      </sec>
      <sec id="article-25207.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with MCTD are at risk for several serious complications, including pulmonary hypertension, interstitial lung disease, and infections, which are significant causes of mortality. In addition, they may develop renal involvement, cardiovascular issues, and gastrointestinal problems, further complicating their clinical management. Early detection and regular monitoring of these complications are essential to improve patient outcomes and reduce the risk of severe health consequences of MCTD.</p>
      </sec>
      <sec id="article-25207.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations for patients with MCTD typically involve a multidisciplinary team approach to address the complex and varied manifestations of the condition. Rheumatologists, pulmonologists, cardiologists, nephrologists, and gastroenterologists often collaborate to provide comprehensive care. Regular consultations with these specialists are crucial for monitoring disease progression, managing complications, and adjusting treatment plans. In addition, patients may benefit from consultations with physical therapists, occupational therapists, and mental health professionals to address the physical and psychological impacts of MCTD. This coordinated approach ensures that all aspects of the patient's health are considered, leading to more effective and holistic management.</p>
      </sec>
      <sec id="article-25207.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education about the disease course and management is vital to improving the quality of life. Discussing the potential organ systems involved in MCTD is important for prompt recognition of complications, and encouraging patient follow-up with specialists for ongoing evaluation and management of those complications is key. Self-care and management of Raynaud phenomenon, including protecting extremities from cold environments, using warming techniques, and recognizing related complications such as nonhealing digital pits or ulcers, is important to preventing digit loss. Active involvement of patients in the decision-making process, especially regarding therapeutics, is also important.</p>
      </sec>
      <sec id="article-25207.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>MCTD&#x000a0;resembles several other CTDs and is easy to misdiagnose. Diagnosis can be challenging due to variable and mixed patient presentations and changes in symptoms&#x000a0;over time. Early diagnosis&#x000a0;is associated with&#x000a0;improved outcomes. Recognizing signs and symptoms and making an early referral to a rheumatologist is crucial. Definitive diagnosis often requires close follow-up and identification of the characteristic clinical, laboratory, and radiologic findings.</p>
        <p>An interprofessional team approach is crucial for improving clinical outcomes and patient quality of life. Pulmonologists, cardiologists, gastroenterologists, and other specialist referrals should be made based on concerns for specific organ involvement. Physicians, advanced practitioners, and nurses should provide coordinated patient education to ensure patients understand the associated signs and symptoms and when to seek medical attention. Pharmacists&#x000a0;must educate patients about the medications used and their potential adverse effects. Pain management should involve pharmacological and nonpharmacological approaches, such as physical therapy and psychological, social,&#x000a0;and emotional support.<xref ref-type="bibr" rid="article-25207.r41">[41]</xref>&#x000a0;This collaborative strategy leverages the expertise of various healthcare professionals and the interprofessional healthcare team&#x000a0;to address the multifaceted nature of MCTD.</p>
      </sec>
      <sec id="article-25207.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25207&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25207">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/mixed-connective-tissue-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25207">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25207/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25207">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25207.s16">
        <title>References</title>
        <ref id="article-25207.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharp</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Irvin</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).</article-title>
            <source>Am J Med</source>
            <year>1972</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>148</fpage>
            <page-range>148-59</page-range>
            <pub-id pub-id-type="pmid">4621694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennett</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Mixed connective tisssue disease: a clinicopathologic study of 20 cases.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1980</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-51</page-range>
            <pub-id pub-id-type="pmid">7414333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunnarsson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hetlevik</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Lilleby</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Molberg</surname>
                <given-names>&#x000d8;</given-names>
              </name>
            </person-group>
            <article-title>Mixed connective tissue disease.</article-title>
            <source>Best Pract Res Clin Rheumatol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <page-range>95-111</page-range>
            <pub-id pub-id-type="pmid">27421219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alarc&#x000f3;n-Segovia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cardiel</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients.</article-title>
            <source>J Rheumatol</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>328</fpage>
            <page-range>328-34</page-range>
            <pub-id pub-id-type="pmid">2724251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuwana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kameda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Muro</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujio</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Itoh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yasuoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fukaya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ashihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ohmura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tabuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsumiya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shirai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsuchida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogawa-Momohara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narazaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyagawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases.</article-title>
            <source>Mod Rheumatol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-33</page-range>
            <pub-id pub-id-type="pmid">31903831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease.</article-title>
            <source>Immunol Med</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>52</fpage>
            <page-range>52-57</page-range>
            <pub-id pub-id-type="pmid">38597289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fl&#x000e5;m</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Gunnarsson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garen</surname>
                <given-names>T</given-names>
              </name>
              <collab>Norwegian MCTD Study Group</collab>
              <name>
                <surname>Lie</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Molberg</surname>
                <given-names>&#x000d8;</given-names>
              </name>
            </person-group>
            <article-title>The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>528</fpage>
            <page-range>528-35</page-range>
            <pub-id pub-id-type="pmid">25187641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Silica associated mixed connective tissue disorder in a stone crusher.</article-title>
            <source>Indian J Occup Environ Med</source>
            <year>2013</year>
            <month>May</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>76</fpage>
            <page-range>76-7</page-range>
            <pub-id pub-id-type="pmid">24421595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prokop</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jagodzinski</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Identification of retroviral conserved pol sequences in serum of mixed connective tissue disease and systemic sclerosis patients.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-4</page-range>
            <pub-id pub-id-type="pmid">14739063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ranki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kurki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Riepponen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stephansson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies.</article-title>
            <source>Arthritis Rheum</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>1483</fpage>
            <page-range>1483-91</page-range>
            <pub-id pub-id-type="pmid">1472125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungprasert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Chowdhary</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Ernste</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Moder</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Mixed Connective Tissue Disease, 1985-2014: A Population-Based Study.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>68</volume>
            <issue>12</issue>
            <fpage>1843</fpage>
            <page-range>1843-1848</page-range>
            <pub-id pub-id-type="pmid">26946215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunnarsson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Molberg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gilboe</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Gran</surname>
                <given-names>JT</given-names>
              </name>
              <collab>PAHNOR1 Study Group</collab>
            </person-group>
            <article-title>The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>1047</fpage>
            <page-range>1047-51</page-range>
            <pub-id pub-id-type="pmid">21398332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chevalier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thoreau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Godeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Agard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Papo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sacre</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seror</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mariette</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benhamou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Levesque</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goujard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lambotte</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bonnotte</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ackermann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Duhaut</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hanslik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Costedoat-Chalumeau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Regent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dunogue</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guern</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Hachulla</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chaigne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation, course, and prognosis of patients with mixed connective tissue disease: A multicenter retrospective cohort.</article-title>
            <source>J Intern Med</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>295</volume>
            <issue>4</issue>
            <fpage>532</fpage>
            <page-range>532-543</page-range>
            <pub-id pub-id-type="pmid">38013625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greidinger</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Zang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Jaimes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nassiri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>CD4+ T cells target epitopes residing within the RNA-binding domain of the U1-70-kDa small nuclear ribonucleoprotein autoantigen and have restricted TCR diversity in an HLA-DR4-transgenic murine model of mixed connective tissue disease.</article-title>
            <source>J Immunol</source>
            <year>2008</year>
            <month>Jun</month>
            <day>15</day>
            <volume>180</volume>
            <issue>12</issue>
            <fpage>8444</fpage>
            <page-range>8444-54</page-range>
            <pub-id pub-id-type="pmid">18523312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tony</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Raghupathy</surname>
              </name>
              <name>
                <surname>V</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malepati</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A Rare Case of Mixed Connective Tissue Disease (MCTD) with Intricate Features of Lupus, Polymyositis and Rheumatoid Arthritis Presenting with Severe Myositis.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>OD05</fpage>
            <page-range>OD05-7</page-range>
            <pub-id pub-id-type="pmid">25954655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venables</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Mixed connective tissue disease.</article-title>
            <source>Lupus</source>
            <year>2006</year>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>132</fpage>
            <page-range>132-7</page-range>
            <pub-id pub-id-type="pmid">16634365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zdrojewicz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Budzy&#x00144;-Kozio&#x00142;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pu&#x00142;awska</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Mixed connective tissue disease--etiology, pathogenesis, clinical significance, treatment].</article-title>
            <source>Postepy Hig Med Dosw</source>
            <year>1999</year>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>751</fpage>
            <page-range>751-66</page-range>
            <pub-id pub-id-type="pmid">10645148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okawa-Takatsuji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aotsuka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uwatoko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takaono</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sumiya</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-54</page-range>
            <pub-id pub-id-type="pmid">11703381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biggiogera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bottone</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Uchiumi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pellicciari</surname>
              </name>
            </person-group>
            <article-title>Still immunodetectable nuclear RNPs are extruded from the cytoplasm of spontaneously apoptotic thymocytes.</article-title>
            <source>Exp Cell Res</source>
            <year>1997</year>
            <month>Aug</month>
            <day>01</day>
            <volume>234</volume>
            <issue>2</issue>
            <fpage>512</fpage>
            <page-range>512-20</page-range>
            <pub-id pub-id-type="pmid">9260922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alves</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Isenberg</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>"Mixed connective tissue disease": a condition in search of an identity.</article-title>
            <source>Clin Exp Med</source>
            <year>2020</year>
            <month>May</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-166</page-range>
            <pub-id pub-id-type="pmid">32130548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ornowska</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wudarski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dziewi&#x00119;cka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Olesi&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Naifold capillaroscopy in mixed connective tissue disease patients.</article-title>
            <source>Clin Rheumatol</source>
            <year>2024</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>1703</fpage>
            <page-range>1703-1709</page-range>
            <pub-id pub-id-type="pmid">38509242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Szilagyi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harshan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Breast involvement in mixed connective tissue disease.</article-title>
            <source>Radiol Case Rep</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>430</fpage>
            <page-range>430-435</page-range>
            <pub-id pub-id-type="pmid">30701011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakashima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kataharada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohsuzu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Panniculitis in a patient with mixed connective tissue disease.</article-title>
            <source>Mod Rheumatol</source>
            <year>2004</year>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-3</page-range>
            <pub-id pub-id-type="pmid">17143684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sullivan</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Hurst</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Harmon</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Esther</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Agia</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Maltby</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lillard</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sunderrajan</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1984</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-107</page-range>
            <pub-id pub-id-type="pmid">6700436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prakash</surname>
                <given-names>UB</given-names>
              </name>
            </person-group>
            <article-title>Lungs in mixed connective tissue disease.</article-title>
            <source>J Thorac Imaging</source>
            <year>1992</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>55</fpage>
            <page-range>55-61</page-range>
            <pub-id pub-id-type="pmid">1578526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungprasert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wannarong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Panichsillapakit</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cheungpasitporn</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Thongprayoon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raddatz</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Cardiac involvement in mixed connective tissue disease: a systematic review.</article-title>
            <source>Int J Cardiol</source>
            <year>2014</year>
            <month>Feb</month>
            <day>15</day>
            <volume>171</volume>
            <issue>3</issue>
            <fpage>326</fpage>
            <page-range>326-30</page-range>
            <pub-id pub-id-type="pmid">24433611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furuya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Onoda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Demura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kashiwazaki</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mixed connective tissue disease associated with protein losing enteropathy: successful treatment with intravenous cyclophosphamide therapy.</article-title>
            <source>Intern Med</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>1359</fpage>
            <page-range>1359-62</page-range>
            <pub-id pub-id-type="pmid">1300171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murakami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moriki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Mixed connective tissue disease developing into MPO-ANCA-positive polyangiitis.</article-title>
            <source>Intern Med</source>
            <year>2011</year>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>591</fpage>
            <page-range>591-5</page-range>
            <pub-id pub-id-type="pmid">21422684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitridou</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Akmal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turkel</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Ehresmann</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Quismorio</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Massry</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1986</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-45</page-range>
            <pub-id pub-id-type="pmid">3563525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennett</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bong</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Spargo</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatric problems in mixed connective tissue disease.</article-title>
            <source>Am J Med</source>
            <year>1978</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>955</fpage>
            <page-range>955-62</page-range>
            <pub-id pub-id-type="pmid">217265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kohat</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Sahu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kansal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fatima</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Headache and cerebral venous sinus thrombosis as a first presentation of mixed connective tissue disease: a rare case and literature review.</article-title>
            <source>Acta Neurol Belg</source>
            <year>2024</year>
            <month>Apr</month>
            <day>07</day>
            <pub-id pub-id-type="pmid">38584238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todoroki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kubo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kosaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fukuyo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakatsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakayamada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2024</year>
            <month>Apr</month>
            <day>02</day>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>1068</fpage>
            <page-range>1068-1075</page-range>
            <pub-id pub-id-type="pmid">37421400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-de la Torre</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Salazar-P&#x000e1;ramo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salm&#x000f3;n-de la Torre</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Mixed connective tissue disease. A clinico-serological study of 17 cases.</article-title>
            <source>Mol Biol Rep</source>
            <year>1996</year>
            <volume>23</volume>
            <issue>3-4</issue>
            <fpage>153</fpage>
            <page-range>153-7</page-range>
            <pub-id pub-id-type="pmid">9112223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takasaki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nawata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsudaira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaneda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease.</article-title>
            <source>Mod Rheumatol</source>
            <year>2004</year>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>367</fpage>
            <page-range>367-75</page-range>
            <pub-id pub-id-type="pmid">17143695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kozuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Johkoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mihara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomiyama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ichikado</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients.</article-title>
            <source>J Thorac Imaging</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-8</page-range>
            <pub-id pub-id-type="pmid">11292211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tashkin</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kleerup</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Goldin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arriola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Volkmann</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Kafaja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wise</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wigley</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mayes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Assassi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dematte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hinchcliff</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Swigris</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meehan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Theodore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simms</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Volkov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schraufnagel</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Scholand</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Frech</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Molitor</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Highland</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Fritzler</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GHJ</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Elashoff</surname>
                <given-names>RM</given-names>
              </name>
              <collab>Sclerodema Lung Study II Investigators</collab>
            </person-group>
            <article-title>Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.</article-title>
            <source>Lancet Respir Med</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>708</fpage>
            <page-range>708-719</page-range>
            <pub-id pub-id-type="pmid">27469583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Tudor</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zanghelini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grossi Sampedro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xydopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Kokosi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoyles</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Parfrey</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Renzoni</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Ashby</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fordham</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Szigeti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molyneaux</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <source>Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT</source>
            <publisher-name>National Institute for Health and Care Research</publisher-name>
            <publisher-loc>Southampton (UK)</publisher-loc>
            <year>2024</year>
            <month>02</month>
            <pub-id pub-id-type="pmid">38422196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hajas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szodoray</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nakken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gaal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Z&#x000f6;ld</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laczik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Demeter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Szekanecz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zeher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bodolay</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical course, prognosis, and causes of death in mixed connective tissue disease.</article-title>
            <source>J Rheumatol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>1134</fpage>
            <page-range>1134-42</page-range>
            <pub-id pub-id-type="pmid">23637328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunnarsson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>El-Hage</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aal&#x000f8;kken</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Reiseter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Garen</surname>
                <given-names>T</given-names>
              </name>
              <collab>Norwegian MCTD study group</collab>
              <name>
                <surname>Molberg</surname>
                <given-names>&#x000d8;</given-names>
              </name>
            </person-group>
            <article-title>Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-8</page-range>
            <pub-id pub-id-type="pmid">26320136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Escol&#x000e0;-Verg&#x000e9;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pinal-Fernandez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fernandez-Codina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Callejas-Moraga</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Espinosa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Labrador-Horrillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Selva-O'Callaghan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mixed Connective Tissue Disease and Epitope Spreading: An Historical Cohort Study.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>155</fpage>
            <page-range>155-159</page-range>
            <pub-id pub-id-type="pmid">28248800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25207.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaigne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scir&#x000e8;</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Talarico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amoura</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Avcin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Beretta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Doria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guffroy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guimar&#x000e3;es</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hachulla</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Krieg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Launay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lepri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moinzadeh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Ladner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rednic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tas</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bombardieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Galetti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mosca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer-Betz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mixed connective tissue disease: state of the art on clinical practice guidelines.</article-title>
            <source>RMD Open</source>
            <year>2018</year>
            <volume>4</volume>
            <issue>Suppl 1</issue>
            <fpage>e000783</fpage>
            <pub-id pub-id-type="pmid">30402271</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
